You know the brand. Let’s discover the business.We’re putting its numbers in order so they tell a clear story.How it makes money, how it’s doing and what could hold it back.Behind every company there’s a lot to tell.Revenue, results and risks, in plain language.One moment: your analysis is being prepared.You know the brand. Let’s discover the business.
Share price multiplied by shares outstanding. It does not measure company cash.
£217.2B
Revenue · FY 2025
?
Sales generated during the period, before costs and expenses.
$58.7B
Net margin · FY 2025
?
Net income as a proportion of revenue.
17.5%
“Our take” and other explanations are generated with artificial intelligence from the data, without human review of each text. They are descriptive, not recommendations. Learn more
Explore questions
Overview
01 · The business
02 · Financial performance
03 · Behind the results
Analysis
04 · Risks
05 · Goals and expectations
Outlook
06 · Valuation
07 · Events
Tracking
08 · Changes since my last visit
P1 · What does it do and how does it make money?
Of every $100 it takes in,40 come from Total Oncology.
Total Oncology is its largest source of revenue (40.3%), followed by CVRM (21.7%). Here you will see what it sells, where, and how that mix is changing.
$59bnrevenue in FY 2025
29business lines with data
47%of sales, in The Americas
Full fiscal year ended Dec 31, 2025
After that close
Q3 2026, ended Sep 30, 2026: total revenue +5.3% against the same quarter a year earlier.
This is the revenue of the whole company. The split by lines and regions on this page is still that of the full fiscal year.
01How it makes money
The data does not separate products from services.
Not all revenue behaves the same way. A one-off sale depends on someone buying again; a service is billed again and again while the customer stays.
Its business lines · FY 2025
02Where revenue comes from
One line weighs far more than the rest.
Each rectangle is a business line and its size is the share of revenue it brings in. Select one to see the detail.
No room for a label in the mosaic
Area = share of total revenue for the year. It does not show profit: the company does not report what each line earns.
Segments add up to $40bn more than total revenue (consolidation adjustments). Weights use the published total.
What is a segment's weight?
The part of everything the company takes in that comes from that line. If a line weighs 49%, then of every 100 in sales, 49 come from it.
How to read it
The more a line weighs, the more revenue depends on it. A high weight is neither good nor bad by itself: it shows where to look first.
03Where sales come from
Sales are spread across several regions.
The Americas is its largest market, with 46.9% of sales. Each square is a region and its area is what it sells there.
Regions from largest to smallest · FY 2025
04How the mix is changing
The mix barely changes.
Weight of each part in 2024 and in 2025. A line gains weight when it grows faster than the total.
Share of revenue in FY 2024 and FY 2025, on one scaleFY 2024FY 2025FY 2024FY 2025Change (pp)
pp = percentage points: the difference between two percentages (from 25% to 27% is 2 pp).
05Read with care
What we can deduce from the data. And what we cannot.
We can deduceWe cannot conclude
01
The net margin jump (13.0% to 17.5% in FY 2025) shows sales turned to profit much more efficiently that year, but it's unknown which line achieved this.
✕That the higher margin comes from particular products or regions: with no profit breakdown, performance by line might vary widely.
Our take
“
AstraZeneca relies on broad product and geographic spread with no dominant line or region, but the profit drivers by segment remain unseen.
01Shown by the figures
Diversification by product and region
No product or region dominates: Oncology is largest but under a quarter, and while the Americas are substantial, Europe and Asia nearly match each other. This is a less singly-dependent profile than many global pharmaceuticals.
02Our interpretation
Missing by-line detail could alter interpretation
Without knowing margin or growth by line, the true stability depends on whether some products contribute more profit than their share of sales suggests. This limits how much diversification really protects the business.
What is not proven
Which products and regions bring the most growth or margin relative to their revenue share: this is not shown here and is crucial to know true dependence.
See the calculations behind it
The Americas brings 46.9% of sales.
With data to Nov 4, 2026. Analysis written by a language model from our calculations, which supply every figure. It is not investment advice.
Next step
Now you know how it makes money. Next: how is it doing?
